Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer “Share Card” Reaches 10% Of 1 Mil. Enrollee Goal In First Week

Executive Summary

Pfizer is approximately 10% of the way to its goal of enrolling 1 mil. participants in the "Share Card" program this year

You may also be interested in...



Pfizer Medicare Rx Priorities: Help “Sell” Bill, Coordinate Share Card

The pharmaceutical industry must help Congress explain the Medicare prescription drug law to seniors, Pfizer VP-Federal Government Relations Kenneth Bowler told a Dec. 9 Institute for International Research conference in Washington, D.C

Pfizer Medicare Rx Priorities: Help “Sell” Bill, Coordinate Share Card

The pharmaceutical industry must help Congress explain the Medicare prescription drug law to seniors, Pfizer VP-Federal Government Relations Kenneth Bowler told a Dec. 9 Institute for International Research conference in Washington, D.C

PhRMA Considering Canada “Key Issues Team” In Response To Import Bills

The Pharmaceutical Research & Manufacturers of America is considering establishing a new "key issues team" focusing on Canadian drug prices

Related Content

UsernamePublicRestriction

Register

PS039228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel